インスリン製剤バイオ後続品の世界市場見通し:持続型バイオシミラー、プリミックスバイオシミラー、速効型バイオシミラー

◆英語タイトル:Insulin Biosimilars - Global Market Outlook (2016-2022)
◆商品コード:SMRC611004
◆発行会社(調査会社):Stratistics MRC
◆発行日:2016年10月
◆ページ数:153
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Single UserUSD4,150 ⇒換算¥448,200見積依頼/購入/質問フォーム
2-5 UserUSD5,250 ⇒換算¥567,000見積依頼/購入/質問フォーム
Global Site LicenseUSD7,500 ⇒換算¥810,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご確認ください。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はStratistics MRC社の日本における正規販売代理店です。Stratistics MRC社の概要及び新刊レポートはこちらでご確認いただけます。
当調査レポートでは、インスリン製剤バイオ後続品の世界市場について調査・分析し、インスリン製剤バイオ後続品の世界市場規模、市場動向、関連企業分析などを含め、以下の構成でお届けいたします。
・エグゼクティブサマリー
・序文
・インスリン製剤バイオ後続品の世界市場:市場動向分析
・インスリン製剤バイオ後続品の世界市場:競争要因分析
・インスリン製剤バイオ後続品の世界市場:セグメント別分析/市場規模
・インスリン製剤バイオ後続品の世界市場:地域別分析/市場規模
・インスリン製剤バイオ後続品の北米市場規模
・インスリン製剤バイオ後続品の欧州市場規模
・インスリン製剤バイオ後続品のアジア市場規模
・インスリン製剤バイオ後続品の世界市場:主な市場開拓
・関連企業分析
【レポートの概要】

According to Stratistics MRC, the Global Insulin Biosimilars market is accounted for $xx million in 2015 and is expected to reach $xx million by 2022 growing at a CAGR of xx% from 2015 to 2022. Growing pervasiveness of type 1 diabetes and ongoing approvals by the government authorities are nurturing the market growth. Some drivers such as growing population exposures, technological developments and favorable medical repayment scenario in developed countries are poised to favour the market growth. However, patent protection rights of Insulin and strong vengeance from the key manufacturers are some of the restraints limiting the market. North America led the insulin biosimilars market due to rising demand for insulin in the region. Europe is anticipated to account for second largest share and Asia Pacific is expected to grow at a fastest rate during the forecast period. APAC players are competing on the basis of price and have pool of patients affected by diabetes, thus fueling the market growth.

Some of the key players operating in the market include Eli Lilly & Co., Boehringer Ingelheim, Merck & Co., Pfizer Inc., Biocon, Mylan N.V., Merck & Co., Pfizer Inc., Sanofi S.A., Ypsomed AG, NOVO Nordisk A/S and Wockhardt Limited.

Disease Indications Covered:
• Type I Diabetes
• Type II Diabetes

Biosimilars Types Covered:
• Long-Acting Biosimilars
• Premixed Biosimilars
• Rapid-Acting Biosimilars

Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o France
o Italy
o UK
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o Rest of Asia Pacific
• Rest of the World
o Middle East
o Brazil
o Argentina
o South Africa
o Egypt

What our report offers:
- Market share assessments for the regional and country level segments
- Market share analysis of the top industry players
- Strategic recommendations for the new entrants
- Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

【レポートの目次】

1 Executive Summary

2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions

3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Emerging Markets

4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 Global Insulin Biosimilars Market, By Disease Indication
5.1 Introduction
5.2 Type I Diabetes
5.3 Type II Diabetes

6 Global Insulin Biosimilars Market, By Biosimilars Type
6.1 Introduction
6.2 Long-Acting Biosimilars
6.3 Premixed Biosimilars
6.4 Rapid-Acting Biosimilars

7 Global Insulin Biosimilars Market, By Geography
7.1 North America
7.1.1 US
7.1.2 Canada
7.1.3 Mexico
7.2 Europe
7.2.1 Germany
7.2.2 France
7.2.3 Italy
7.2.4 UK
7.2.5 Spain
7.2.6 Rest of Europe
7.3 Asia Pacific
7.3.1 Japan
7.3.2 China
7.3.3 India
7.3.4 Australia
7.3.5 New Zealand
7.3.6 Rest of Asia Pacific
7.4 Rest of the World
7.4.1 Middle East
7.4.2 Brazil
7.4.3 Argentina
7.4.4 South Africa
7.4.5 Egypt

8 Key Developments
8.1 Agreements, Partnerships, Collaborations and Joint Ventures
8.2 Acquisitions & Mergers
8.3 New Product Launch
8.4 Expansions
8.5 Other Key Strategies

9 Company Profiling
9.1 Eli Lilly & Co.
9.2 Boehringer Ingelheim GmbH
9.3 Biocon Limited
9.4 Mylan N.V.
9.5 Merck & Co.
9.6 Pfizer Inc.
9.7 Sanofi S.A.
9.8 Ypsomed AG
9.9 NOVO Nordisk A/S
9.10 Wockhardt Limited

List of Tables
Table 1 Global Insulin Biosimilars Market Outlook, By Region (2013-2022) ($MN)
Table 2 Global Insulin Biosimilars Market Outlook, By Disease Indication (2013-2022) ($MN)
Table 3 Global Insulin Biosimilars Market Outlook, By Type I Diabetes (2013-2022) ($MN)
Table 4 Global Insulin Biosimilars Market Outlook, By Type II Diabetes (2013-2022) ($MN)
Table 5 Global Insulin Biosimilars Market Outlook, By Biosimilars Type (2013-2022) ($MN)
Table 6 Global Insulin Biosimilars Market Outlook, By Long-Acting Biosimilars (2013-2022) ($MN)
Table 7 Global Insulin Biosimilars Market Outlook, By Premixed Biosimilars (2013-2022) ($MN)
Table 8 Global Insulin Biosimilars Market Outlook, By Rapid-Acting Biosimilars (2013-2022) ($MN)
Table 9 North America Insulin Biosimilars Market Outlook, By Country (2013-2022) ($MN)
Table 10 North America Insulin Biosimilars Market Outlook, By Disease Indication (2013-2022) ($MN)
Table 11 North America Insulin Biosimilars Market Outlook, By Type I Diabetes (2013-2022) ($MN)
Table 12 North America Insulin Biosimilars Market Outlook, By Type II Diabetes (2013-2022) ($MN)
Table 13 North America Insulin Biosimilars Market Outlook, By Biosimilars Type (2013-2022) ($MN)
Table 14 North America Insulin Biosimilars Market Outlook, By Long-Acting Biosimilars (2013-2022) ($MN)
Table 15 North America Insulin Biosimilars Market Outlook, By Premixed Biosimilars (2013-2022) ($MN)
Table 16 North America Insulin Biosimilars Market Outlook, By Rapid-Acting Biosimilars (2013-2022) ($MN)
Table 17 Europe Insulin Biosimilars Market Outlook, By Country (2013-2022) ($MN)
Table 18 Europe Insulin Biosimilars Market Outlook, By Disease Indication (2013-2022) ($MN)
Table 19 Europe Insulin Biosimilars Market Outlook, By Type I Diabetes (2013-2022) ($MN)
Table 20 Europe Insulin Biosimilars Market Outlook, By Type II Diabetes (2013-2022) ($MN)
Table 21 Europe Insulin Biosimilars Market Outlook, By Biosimilars Type (2013-2022) ($MN)
Table 22 Europe Insulin Biosimilars Market Outlook, By Long-Acting Biosimilars (2013-2022) ($MN)
Table 23 Europe Insulin Biosimilars Market Outlook, By Premixed Biosimilars (2013-2022) ($MN)
Table 24 Europe Insulin Biosimilars Market Outlook, By Rapid-Acting Biosimilars (2013-2022) ($MN)
Table 25 Asia Pacific Insulin Biosimilars Market Outlook, By Country (2013-2022) ($MN)
Table 26 Asia Pacific Insulin Biosimilars Market Outlook, By Disease Indication (2013-2022) ($MN)
Table 27 Asia Pacific Insulin Biosimilars Market Outlook, By Type I Diabetes (2013-2022) ($MN)
Table 28 Asia Pacific Insulin Biosimilars Market Outlook, By Type II Diabetes (2013-2022) ($MN)
Table 29 Asia Pacific Insulin Biosimilars Market Outlook, By Biosimilars Type (2013-2022) ($MN)
Table 30 Asia Pacific Insulin Biosimilars Market Outlook, By Long-Acting Biosimilars (2013-2022) ($MN)
Table 31 Asia Pacific Insulin Biosimilars Market Outlook, By Premixed Biosimilars (2013-2022) ($MN)
Table 32 Asia Pacific Insulin Biosimilars Market Outlook, By Rapid-Acting Biosimilars (2013-2022) ($MN)
Table 33 RoW Insulin Biosimilars Market Outlook, By Country (2013-2022) ($MN)
Table 34 RoW Insulin Biosimilars Market Outlook, By Disease Indication (2013-2022) ($MN)
Table 35 RoW Insulin Biosimilars Market Outlook, By Type I Diabetes (2013-2022) ($MN)
Table 36 RoW Insulin Biosimilars Market Outlook, By Type II Diabetes (2013-2022) ($MN)
Table 37 RoW Insulin Biosimilars Market Outlook, By Biosimilars Type (2013-2022) ($MN)
Table 38 RoW Insulin Biosimilars Market Outlook, By Long-Acting Biosimilars (2013-2022) ($MN)
Table 39 RoW Insulin Biosimilars Market Outlook, By Premixed Biosimilars (2013-2022) ($MN)
Table 40 RoW Insulin Biosimilars Market Outlook, By Rapid-Acting Biosimilars (2013-2022) ($MN)



【レポートのキーワード】

インスリン製剤バイオ後続品、持続型バイオシミラー、プリミックスバイオシミラー、速効型バイオシミラー

★調査レポート[インスリン製剤バイオ後続品の世界市場見通し:持続型バイオシミラー、プリミックスバイオシミラー、速効型バイオシミラー] (コード:SMRC611004)販売に関する免責事項を必ずご確認ください。
★調査レポート[インスリン製剤バイオ後続品の世界市場見通し:持続型バイオシミラー、プリミックスバイオシミラー、速効型バイオシミラー]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆